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Computer Program Simulates Cell Growth,
Provides Data for Cytotoxic Drug Studies
A new computer program developed at UT MDAH can simulate
and graphically display the simultaneous growth and interaction
of two cell populations, such as tumor cells and normal cells.
This program, entitled CELLGROW, was developed by Elton
Stubblefield, PhD, Department of Genetics. CELLGROW is
primarily used to plan drug experiments in tissue culture and to
aid in teaching cell kinetics. To operate the program, which runs
on an Apple 11, II+, or lie computer, one need not have computer
knowledge, only an understanding of cellular growth.
A unique feature of CELLGROW is its ability to display the cell
division and multiplication of two cell populations at once. Cells of
both populations are shown on the monitor as colored squares
that may change color as they progress through the phases of the
cell cycle. The program can color code each cell phase so that
the color of a cell may indicate its particular phase of growth at a
given moment. The two cell populations are usually distinguished
from one another by variation in movement or distribution.
Simulation data, including tables and graphs of population
kinetics, are printed out at the end of the experiment. These show
the number of cells in each phase and the total cell population for
both populations at any point in the experiment.
Before beginning the simulated experiment, the operator must
input for each cell population the cell cycle parameters of time
and motion that determine the characteristics of cell growth.
Values for these parameters will differ in population 1 and
population 2.
The first parameter is time for cell division, which involves
assigning a specific time to each phase of the cell cycle. In
experiments that simulate the growth of certain types of tissue,
the rate of cell division in these tissues will determine the
simulated cell cycle time. For example, epithelial cells may

require 18 hours for cell division in contrast to fibroblasts, which
may divide in 12 to 14 hours. On the average, the G1 phase is
approximately 5 hours, the S phase 8 hours, the G2 phase 2.5
hours, and mitosis .5 hours. On the computer, cells proceed
through these phases of the cell cycle in a proportional number of
minutes. In addition to cell cycle time, the desired number of cell
divisions must also be input.
This program also allows cells at specific times to enter and
leave the GO phase, a kind of holding state in which certain cells
may remain indefinitely without dividing. In the body, specialized
cells may remain in the GO phase, unless they are recruited into
the cell cycle for performing a specialized task. Fibroblasts, for
example, reenter the cell cycle from the GO phase to heal wounds
and form scar tissue. After the task is complete, these specialized
cells return to the GO phase.
Another parameter of cell growth that must be given a value is
motion. Assigned values from 1 to 1O will determine the degree of
cellular activity, whether stationary or active, and the direction of
cell movement on the screen, whether random or preferentialup, down, right, or left. Values can be input that allow for the
simulation of cellular activity of a certain kind of tissue; this often
involves assigning the two cell populations different motion
factors. If population 1, for example, is given a value of O and
remains stationary and population 2 is assigned a value of 3 with
movement to the right, a cell kinetic situation is set up that
simulates cell growth in the skin. As Dr Stubblefield explained,
"Sitting at the base of the dermis are stem cells dividing like
population 1 cells, producing cells that migrate out toward the
surface of the skin and differentiate into new skin cells, population
2 cells, which eventually die and are washed away."
Continued on page 7

The computer printouts shown above represent cell populations as they appeared on the computer screen during a simulated experiment
at 98 hours (left) and 120 hours (right). As in a comparable tissue culture experiment, the simulated tumor cells (bottom center in both
illustrations), which grew from a single cell, are compact and stationary. In contrast, the normal cells (clear squares) are randomly
distributed. The experiment was set up so that one out of 1000 normal cell divisions would give rise to a tumor cell.

UT MDAH Code of Ethics Guides Personnel in
Making Complex Decisions Concerning Patients
UT MDAH has recently drafted a code of ethics to guide
personnel in making professional decisions concerning patients.
The code of ethics, the first to be adopted by a comprehensive
cancer center, was written by a seven-member committee
headed by Charles A. LeMaistre, MD, president of The University
of Texas System Cancer Center; Jan van Eys, MD, PhD, head of
the Division of Pediatrics; and James M. Bowen, PhD, vice
president for academic affairs.
In stating the need for such a code at UT MDAH, Dr LeMaistre
said, "We find crucial ethical issues confronting our hospital staff
every day. This code will serve as a framework for the staff in
managing complex matters constantly arising in the care of
patients in a research setting."
The code, drafted for all personnel, helps to set priorities
concerning the institution's goals of advancing science and
promoting patient care. The code is viewed by many as a
statement assuring each patient that staff decisions, whether
large or small, will always be made in the patient's best interest.
"Our position is not just to advance science, but rather to help
people," Dr LeMaistre affirmed.
All codes deal with a balance between meting out mercy and
dispensing justice, Dr van Eys explained. He said, "In a sense,
our efforts at the basic science level are our efforts toward justice,
and our clinical efforts are our gestures of mercy. We must be
cognizant of the equal need for all when faced with the problem of
cancer."

The code of ethics follows:
CODE OF ETHICS

Preamble
Our institution is a specialized center devoted to the care of
patients with cancer and to the prevention and eradication of
malignant disease. We strive to combine the activities of patient
care, education, and research to benefit not only patients
currently receiving care but also future generations. In this
diversity, there is often ·tension; therefore, we hold before us thft
Code of basic moral principles against which to measure our
service and to bond patients and staff together in the difficult task
of contending with cancer.

Principle 1
Reverence for the patients for whom we are privileged to care is
our primary concern. Such reverence affirms the value and
dignity of life.

Principle 2
Acknowledging the value and dignity of life, we dedicate ourselves to provide our best care and to use our knowledge to
attempt cure of the disease in each patient while pursuing
understanding of the basic biologic nature and eradication of
cancer.

Principle 3
The presence of cancer may justify, but not demand, heroic
measures. Curing disease, reducing suffering, and sustaining an
acceptable quality of life, as defined by the patient with the help of
health-care professionals, are central goals of this institution.

President, The University of Texas System Cancer Center:
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Vice President for Academic Affairs:
James M. Bowen, PhD
Associate Vice President for Academic Affairs:
Robin R. Sandefur, PhD
Head, Department of Scientific Publications:
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Editor: Margaret G. Small, MA
Writer: Sally W. Ridgway, MEd
Art and Photography: Department of Biomedical
Communication
Published quarterly by the Department of Scientific Publications, Division of Academic Affairs, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030.
Made possible by a gift from Mrs Harry C. Wiess.

Principle 4

- ·

All who serve in this institution have specific tasks and roles, yet
all are equal as potential friends to patients. Because of these
vocational and personal bonds, each of us bears individual moral
obligations to each patient.

Principle 5
Knowledge-seeking research and knowledge-disseminating instruction are valued institutional goals. These pursuits require at
,east mree conamons: paruc1pants wno are intormea about nsKs
and benefits; actions that do not undermine the patients' therapeutic needs; the transmission of truthful information that is
based on sound evidence.

Principle 6
The diagnosis of cancer is not just an identification of a disease
but also carries with it a potential burden for patients, who may
Continued on page 6
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Epidemiologist Relates Hodgkin's Disease,
Testicular Cancer, and Multiple Sclerosis
The epidemiologic similarities among multiple sclerosis, Hodgkin's disease, and testicular cancer suggest that these diseases
may be caused by viral agents that have a common mode of
infection, according to Guy R. Newell, MD, chairman of the
Department of Cancer Prevention.
All three diseases appear to follow the paralytic poliomyelitis
model: widespread geographic differences in occurrence of
disease with infection by an agent of low pathogenicity. When
contracted at an early age, infection with poliomyelitis virus
results in lifetime immunity. If infection occurs at adolescence or
young adulthood, paralytic poliomyelitis, a different and much
more severe disease, develops.
Dr Newell and coworkers, Douglas E. Johnson, MD, Department of Urology, and Paul K. Mills, MPH,* Department of Cancer
Prevention, formulated this theory from data suggesting epidemiologic similarities among the three diseases in age at onset,
geographic distribution, socioeconomic level affected, racial
groups affected, and size of the victim's family.
Data showed that the three diseases have peak occurrences in
individuals between 20 and 40 years of age. Individuals generally
contract multiple sclerosis around age 30. The peak incidence of
Hodgkin's disease is between ages 20 and 30 and after age 50.
Peak incidence of testicular cancer is between ages 25 and 34
and, to a lesser degree, between ages 45 and 50.
For both Hodgkin's disease and testicular cancer, histologic
type of disease is related to age at disease onset, suggesting the
possibility of infection by different agents or disease subtypes in
different age groups. In testicular cancer, germ cell tumors
account for 95% of all testicular tumors. Choriocarcinoma,
teratoma, embryonal carcinoma, and seminoma, which comprises 35% to 71 % of these four tumors, are the most common
germ cell tumor types. Those contracting testicular cancer at
adolescence and in their 20s have nonseminoma germ cell
tumors. The nonseminomatous tumor that occurs at age 15 may
be caused by a different agent than a seminoma occurring at age
35, Dr Newell explained.
The histologic types of Hodgkin's disease also tend to be agerelated. Hodgkin's disease is divided into four histologic groups:
(1) lymphocytic predominance, (2) nodular sclerosis, (3) mixed
cellularity, and (4) lymphocytic depletion. Nodular sclerosis often
occurs in persons around 30 years of age and older; the
remaining three histologic types usually occur in older Hodgkin's
disease patients. In young adults, Hodgkin's disease appears to
be caused by a virus of low pathogenicity, but in the elderly the
disease may have a nonviral cause similar to causes of other
malignancies, Dr Newell explained. Current epidemiologic studies
of these histologic types indicate that Hodgkin's disease may
actually be two or more diseases that affect individuals at
different ages.
Data suggesting similarities in geographic distribution of the
three diseases show a decline in occurrence of each from north
*No longer at UT MDAH.
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Fig. 1. Age-specific
incidence rates for
testicular cancer
(TC) and Hodgkin's
disease (HD) in
white males in the
U.S. In both diseases, peak incidence occurs in individuals of two age
groups, those between 20 and 30
years of age and
those older than 40.

Age
to south. They appear more frequently in countries with temperate climates, except for Japan where these diseases, especially
multiple sclerosis, are rare. Incidence rates for all three diseases
are high in the U.S. and in European countries; these diseases
occur infrequently in Africa and among black populations in
general.
The three diseases also occur more frequently in economically
advanced areas and high socioeconomic groups where early
exposure to disease is less common than in impoverished areas.
As Dr Newell explained, "In developing countries with poor
sanitation, infection is widespread at an early age. However,
children may escape infection in economically advanced societies, often having home environments more protective against
disease. Not having acquired an early immunity, older children or
young adults are susceptible to these diseases." Although Japan
is economically advanced, its low disease rates might be
attributed to early exposure of the population to disease-causing
agents in "night soil," a widely used fertilizer containing human
excrement, Dr Newell speculated.
Family size appears to affect risk as well; the greater the
number of children in a family, the greater the likelihood of early
exposure to infection. Children of small families are, thus, less
likely to be exposed and will be more susceptible to disease at a
later age.
Evidence linking Hodgkin's disease to several diseases of the
central nervous system, similar to multiple sclerosis, lends
support to Dr Newell's infectious disease theory. Recent studies
have found a predisposition to Hodgkin's disease and other
lymphomas in relatives of patients with Alzheimer's sclerosis, one
of the presenile dementias. Like Hodgkin's disease and multiple
sclerosis, Alzheimer's sclerosis has been associated with a slowvirus etiology. Hodgkin's disease has also been linked with
progressive multifocal leukoencephalopathy (PML). PML is a
Continued on page 6
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Leech Gland Extract Inhibits Metastasis
Table 1. SGP' Effect on Cyclophosphamide-lnduced Enhancement of Metastases in Mice Injected with Tumor Cells
Fibrosarcoma*

Sarcomat
Treatment of
tumor cell
recipients

Median no.
(range)
of lung nodules

No. of mice with
metastases/total
no. of mice
Mediastinum

Lung

4/10

10/10
2/10
10/10

p§

No. of mice with
metastases/total
no. of mice

Median no.
(range)
of lung nodules

p§

Lung

Hepes buffer,

day0
SGE, day 0
CY, II day -1
CY, day -1 +
SGE, day 0
CY, day -4
CY, day -4 +
SGE, day 0
CY+ SGE, day -4

0/10
10/10

19 ( 15- 35)}
0 ( 0- 1)

<.001

122 ( 50-140)}

7/9
1/9
not administered

2 ( 0- 6)}
0 ( 0- 1)

< .01

<.001

4/10

3/10
10/10

20 (

10/10

7- 60)

177 (100-232)}

not administered
10/10

48(35-65)}

10/10
9/9

26 ( 5-73) }
22 (10-33)

< .05

.001
5/10

10/10
not
administered

10 (

5- 76)

< .01

• Salivary gland extract from Haementeria officinalis, 3 doses of 500-800 µg given every 2 hours.

t Lung tumors were counted 19 days after i.v. inoculation of 5

x 104 sarcoma cells.

*Lung nodules were counted 14 days after i.v. inoculation of 2 x 10

4

fibrosarcoma cells.

§ Mann-Whitney U test.

II

Cyclophosphamide (CY) 200 mg/kg body weight i.p.

Salivary gland extract (SGE) from the Mexican leech, Haemencolonization persisted for months. Although the clinical implicateria officinalis, has been found to inhibit in mice enhancement of
tions of these findings are uncertain, such agents may have a
lung metastasis caused by treatment with cyclophosphamide or
similar metastasis-enhancing effect in humans, Dr Milas exlocal thoracic irradiation.
plained.
This finding is the result of a study conducted by Gabriel J.
SGE was investigated in the present study as a possible
Gasic, MD, PhD, and coworkers at Pennsylvania Hospital in
metastasis inhibitor because of its anticoagulant and antiplatelet
Philadelphia, in collaboration with Luka Milas, MD, PhD, chairaggregating activity thought to prevent tumor cell lodgement and
man of the Department of Experimental Radiotherapy at UT
to enhance release of these cells from the lung.
MDAH.
The effects of SGE were compared in mice inoculated with
Radiation and cytotoxic drugs, by causing normal tissue
syngeneic mouse tumor cells and either pretreated with cyclodamage, are thought to promote metastasis to these tissues if
phosphamide (200 mg/kg of body weight) or local thoracic
they do not first completely sterilize the source of circulating
irradiation (1000 rad) or not treated prior to tumor cell inocutumor cells. This may occur when chemotherapy or radiation
lation. Cyclophosphamide was administered 1 or 4 days before
- ~ d'. ""'e_.. _st"...:ro~v~s~m~o~
re~n~o~r_!_'
m_...a._._l~ti~
ss~u~e.._.t. __,h""
a"---'
n_._tu. .,m'---'---""o,_
r _.tis
_.,,.,,s...,u"'e._,___,....
a,.,_
sJ.J.in-'-lpl-'-'r'-"'o,. .p"-'
hy"~l.....
a...,ct_.._.i...__
c _ _ ~ i,l lOCUJatio~ceUs.-and--k>ca.l-----Uloracie-mad.fi,1ial½lti{¾on
1-t-- - -irradiation when the primary tumor is still uncontrolled and in the
was given 1 day before. Lung metastases were generated by
use of chemotherapy or irradiation for tumors later found to be
inoculation of 2 x 104 to 6 x 104 mouse sarcoma or fibrosardrug- or radioresistant. "Tumors resistant to treatment continue to
coma cells; 2.5 x 104 sarcoma cells generated growth in the
shed tumor cells into the circulation, which may find normal
mediastinum.
tissues preconditioned by radiation or chemotherapy for the
For further comparison, mice in each treatment group were
establishment of secondary growths," Dr Milas said. Tumor cells
divided into those who received SGE (three doses of 500 to 800
are thought to lodge more easily in such damaged tissues.
µg of protein in 0.2 ml of Hepes CaCl 2 buffer per injection) and
Lung tissue, a common site of metastasis, has been studied to
those who did not. SGE was administered by intravenous (i.v.) or
determine the metastasis-enhancing effect of these modalities. In
intraperitoneal (i.p.) injection on the day of local thoracic irradiaone study, when tumor cells were injected into mice pretreated
tion, cyclophosphamide administration, or tumor cell inoculation.
with cyclophosphamide, lung colonization increased 1000 times
Fourteen or 19 days after tumor cell inoculation, mice were
that occurring in untreated animals. In these animals and others
killed, and results were determined. SGE almost totally abolished
treated with local thoracic irradiation, susceptibility to lung
metastasis formation in the mediastinum and lungs of control
4
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Enhancement by Drugs or Radiation in Mice
mice inoculated with sarcoma . or fibrosarcoma cells (Table 1).
SGE also greatly inhibited cyclophosphamide enhancement of

days prior to sarcoma cell administration, total mediastinal weight
was 1230 mg; tumor masses of five mice receiving SGE on the

metastasis at both sites: SGE totally abolished sarcoma metas-

day of cyclophosphamide injection weighed 710 mg. Thus when

tasis enhancement by cyclophosphamide and reduced fibrosar-

comparing the reduction in size and weight of the sarcoma tumor

coma metastasis enhancement by about 50%. The greatest

in control and treatment groups, SGE totally abolished cyclo-

reduction of metastasis enhancement occurred when cyclophos-

phosphamide-induced metastasis enhancement, Dr Milas explained.

phamide was administered 1 day before sarcoma cell inoculation
and SG E on the day of inoculation (Table 1 ). SGE also greatly

To determine the mechanism of action of SGE, researchers

reduced enhancement of tumor metastases induced by local
thoracic irradiation whether SGE was given on the day of
fibrosarcoma cell injection or the day of local thoracic irradiation,

tested SGE's ability to accelerate tumor cell clearance from the
lung. This experiment involved measurements of lung radioactivity in mice inoculated with 125 I-UDR-labeled sarcoma cells and
pretreated with cyclophosphamide 4 days before; these mice

administered 1 day before tumor cell injection (Table 2) .
SG E, administered on the day of tumor cell inoculation, also

were given a single injection of 1500 µg protein SGE 2 hours

reduced the size of the sarcoma lung colonies measured in

before tumor cell injection. In addition, radioactively labeled
tumor cells were injected and retention determined in mice that

normal mice and in m ice pretreated with cyclophosphamide. It
reduced the average size of sarcoma nodules from 2.4 ± 0.4 mm
to 1.0 ± 0.1 mm in control mice ; in those receiving cyclophos-

received cyclophosphamide alone or SGE alone and in control
mice receiving Hepes buffer only. The radioactivity of the lung

phamide 4 days prior to tumor cell inoculation, average sarcoma

was measured at 10 minutes and 2, 4, and 8 hours after tumor

nodule size decreased from 3.3 ± 0.3 mm to 1. 7 ± 0.8 mm.

cell injection. Initially at 10 minutes, 85% to 95% of tumor cells

Similar findings were obtained when the weight of tumor tissue

were retained in the lung in all groups. Thereafter, however, at 8

removed from the mediastinum of control mice and of mice

hours the control mice retained 42% ± 3% of cells, and the cyclo-

treated by cyclophosphamide was compared. The total weight of

phosphamide-treated mice not receiving SGE, 68% ± 8% of

tumor masses from five mice that received the sarcoma cells only

cells. In those receiving SGE alone, retention of tumor cells was

was 882 mg; in five mice that received cyclophosphamide only 4

reduced to 18% ± 1% at 8 hours. In mice pretreated with cyclophosphamide and receiving SGE, tumor cell retention was
reduced to 38% ± 12% at 8 hours. SGE (500 µg protein) also
reduced lung retention of tumor cells in cyclophosphamide-

Table 2. SGF' Effect on LT/t-lnduced Enhancement of

treated animals when the extract was given in three injections 2

Lung Metastases in Mice Injected with Tumor Cells

hours before and 2 and 4 hours after tumor cell inoculation.

-

Further testing indicated that increased tumor clearance was
Experiment 2

Experiment 1

P§

Median no.

Treatment of

(range)
of lung nodules:t

tumor cell
recipients

Median no.
(range)
of lung nodules:t

P§

not due to any cytotoxic effect of SGE or augmentation of natural
killer cells by SGE. Instead, SGE was found to reduce metastasis
enhancement by interfering with factors responsible for the cyclophosphamide effect. This was concluded because SGE reduced
lung nodules when administered alone on the same day or 1 day
before tumor cell administration, but not when given alone 4 days
before tumor cell injection. However, SGE was similarly effective

Hepes buffer,
day0

46 (43- 71)}
9 ( 3- 16)
134 (31-158)

SGE, day 0
LTI, day -1
LTI & SGE,

3 (0-10) II }
0 (0- 3)#

administered

<.05tt

4 days after cyclophosphamide. In addition, when SGE was given

<.001

cell injection, the number of metastatic nodules decreased . SGE,

.01

administered with cyclophosphamide and, therefore, must have
interfered with the cyclophosphamide metastasis-enhancing ef-

with cyclophosphamide on the same day but 4 days before tumor
then, had no effect when given 4 days before tumor cells unless

2 (1- 8)

+

SGE, day 0

.01

9 (3-20)}

not

day -1
LTI, day -1

.001

whether given several hours before or after cyclophosphamide or

2 (1-16J

66 ( 32- 85)

fect.
Investigators attributed several factors to SGE's effect. Because SGE exhibits strong anticoagulant and antiplatelet ag* Salivary gland extract from Haementeria officinalis, 3 doses of 600 µ,g given i. v.

every 2 hours.

t Local thoracic irradiation, 1000 rad.

:t Lung nodules were counted 14 days after i.v. inoculation of 3 x 104 (Exp. 1) or
6 x 104 (Exp. 2) fibrosarcoma cells.
§ Mann-Whitney U test.
II 8 of 10 mice had metastases.
# 3 of 10 mice had metastases.
tt P value for LTl , day - 1 and LTl , day -1

Vol. 29, No. 4

gregating activities, it may interfere with the accumulation of
platelets around tumor cells and the formation of fibrin clots that
facilitate vascular lodgement by tumor cells. In addition, because
local thoracic irradiation and cyclophosphamide damage capillaries, causing gaps in the capillary endothelial lining, tumor cells

+

SGE, day 0.

Continued on page 8
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Epidemiologist
Continued from page 3

disease of the central nervous system that is caused by a papova
virus. Some patients with PML have underlying malignancies
such as Hodgkin's disease that impair cell-mediated immunity.
These malignancies may, in fact, predispose patients to PML.
Hodgkin's disease is also associated with subacute motor
neuronopathy (SMN), which may develop late in the course of
Hodgkin's disease or other lymphomas. SMN causes neuronal
degeneration primarily of the anterior horn cells of the spinal cord,
producing lesions very similar to those seen in paralytic poliomyelitis. Since Hodgkin's disease and paralytic poliomyelitis are
epidemiologically similar, this finding may provide a valuable clue
to the interrelation of these diseases.
Hodgkin's disease, multiple sclerosis, and testicular cancer,
then, may each be explained in terms of an environmental
infectious agent or agents of uneven worldwide distribution that.

generally have low levels of pathogenicity. Each disease occurs
infrequently and in response to a given set of host factors that are
not yet clearly understood. Testicular cancer and Hodgkin's
disease each may be caused by several different agents working
in combination or by a diverse histologic response to a single
agent. Myxoviruses, slow viruses, and enteric and respiratory
viruses are presently being investigated as possible causes for
the three diseases.
A comparison of similar epidemiologic features is of value
because it suggests a plausible hypothesis that, after further
epidemiologic, clinical, and laboratory studies, may shed some
light on the causes of these diseases. As Dr Newell explained,
"Such studies may enable us to identify the etiologic agent
involved and then take the intervening steps to prevent the
disease."
(Physicians desiring additional information should write or call
Guy R. Newell, MD, Department of Cancer Prevention, MDAH
Box 189, The University of Texas M. D. Anderson Hospital and
Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030 (713) 792-3020.-ED)

Code of Ethics
Continued from page 2
feel stigmatized, and for those close to them, who share the
impact. We must understand their perceptions and help them to
come to terms with their altered lives.

The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston
2nd Annual Administrative Conference

Principle 7
Patients justly expect personal information to be confidential, yet
their medical records are accessible to all health-care providers.
All information must be recorded responsibly. Access also
confers a moral obligation. Access must be justified and not
harmful to the patients' interests.

Administrative Aspects of
Home Health Care
February 1, 1985

Prlnclple 8
Since our specialized roles result in varying levels of function and
decision-making, we affirm the need to demonstrate mutual
respect and to acknowledge interdependence as coworkers
responsible for the welfare of patients.

Principle 9
The immediacy of patient care tends to obscure the relevance of
basic biologic research. We affirm that research, responsibly
conceived and scientifically sound, establishes an environment of
learning, encourages exacting practice, fosters new knowledge,
and creates realistic prospects of eradicating cancer, thus
promoting a favorable balance of risks and benefits.

Principle 1O
Cancer therapy and research are expensive endeavors demanding conscientious stewardship; however, financial considerations
should never dictate the quality of care offered to each patient.

6

Four Seasons Hotel
Houston Center
Houston, Texas
Chairperson: Donald B. Wagner, MA, associate vice
president for patient care operations
The conference will discuss: organizational, regulatory,
and financial issues in the development of home healthcare programs; the physician's perspective on home
health care; and the hospice as an alternative to hospital
care.
For registration information, write or call the Office of
Conference Services, HMB Box 131, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.
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Computer Program
Continued from page 1

The means by which population 2 cells arise must also be
determined before the simulated experiment begins. There are
four methods of creating population 2 cells. In one, a fraction of
daughter cells from population 1 can become population 2 cells
after mitosis. In a second, a fraction of GO cells from population 1
may reenter the cell cycle as population 2. This method may be
used in simulating drug experiments with tumor cells in culture.
Tumors often have cells in the GO phase that may reenter the cell
cycle at any time. These GO-phase cells can influence the
effectiveness of a drug and, therefore, must be included in a
simulated drug experiment. In a third method, a fraction of
population 1 cells may become population 2 cells after passing
through a particular cell cycle phase. This method is useful in
simulating drug experiments in which cells in a certain phase are
radiolabeled to determine what percentage of the original cell
population was killed by a drug that is cytotoxic in that phase. By
a fourth method, population 2 cells may be created at the
beginning of the experiment as a separate unrelated population
of cells.
In addition to the above-mentioned situations, this program can
be used to simulate other cell growth experiments in culture, also
involving the effects of certain drugs. Many drugs are cytotoxic
only in particular phases of the cell cycle, usually when cells are
duplicating their chromosomes in the S phase or in mitosis. In two
cell populations, normal cells and tumor cells, for example, if a
drug is used that kills cells in S phase and if the normal population
1 has a much longer G 1 phase and shorter S phase than the
cancerous population 2, then by simulating these circumstances,
the length of time of S-phase cell kill for maximal kill of tumor cells
and minimal harm to healthy cells can be determined. This
information then indicates how long a drug should remain in
culture to achieve the most effective results.
The computer can also be used to simulate experiments in
which a drug blocks, or immobilizes, cells in a certain phase to
synchronize the cell growth of different cell populations. Vinblastine, for example, blocks cells in mitosis. The program can
determine how long vinblastine should remain in the culture to
achieve maximum synchronization of cell populations. On the
computer screen, all cells passing through mitosis, represented
as orange squares, would remain static for the length of time
assigned to the cell block. At the end of that time, the cells, or
colored squares, would begin dividing again.
When the simulated experiment is complete, a dot-matrix
printer prints out population data as it appeared on the screen
and in graphs and charts. The total cell population influenced by
different variables at different time intervals during the entire
experiment is depicted in these illustrations. This ability to
immediately assimilate information concerning cell growth is the
primary benefit of CELLGROW. As Dr Stubblefield explained, "It
may take all afternoon to compile data from an experiment and
draw a graph. But the computer does it instantly."
In the near future, Dr Stubblefield plans to develop a computer
program to simulate embryonic growth in three dimensions. The
Vol. 29, No. 4

computer would be capable of showing a slice through a threedimensional embryo at any point in embryonic growth. This
program, which will require the use of a super computer, should
determine the factors invo~ved in cellular differentiation and
embryonic development and may help to explain how cancer is a
variant of normal growth.
According to Dr Stubblefield, the value of CELLGROW is its
ability to make a summary statement of everything known about
the growth of certain cell populations. Such a vast amount of
information would be almost impossible to assimilate by means
other than computer. CELLGROW is also a first step in the
development of more complex programs that may clarify the
interrelation of cell populations and thus determine how cancer
cells arise, Dr Stubblefield explained.
(Physicians desiring additional information should write or call
Travis E. Stubblefield, PhD, Department of Genetics, MDAH Box
6, The University of Texas M. D. Anderson Hospital and Tumor
Institute at Houston, 6723 Bertner Avenue, Houston, Texas
77030 (713) 792-2581.-ED)

The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston

38th Annual Symposium
On Fundamental Cancer Research

Immunology and Cancer
February 26-March 1, 1985
Shamrock Hilton Hotel
Houston, Texas
Cochairpersons: Margaret L. Kripke, PhD, chairman of the
Department of Immunology, and James P. Allison, PhD,
Division of Research, The University of Texas Science
Park
This symposium will present new ideas in immunologic
approaches to cancer treatment. Topics of discussion
include: immune recognition by T and B cells; cellular
communication and interaction; immune responses to
cancer; immunologic effector mechanisms; immunologic
approaches to cancer therapy.
For registration information, write or call the Office of
Conference Services, HMB Box 131, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.
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Leech Extract
Continued from page S
can more easily attach to the capillary wall. Once attached, tumor
cells, by secreting proteolytic enzymes that destroy components
of capillary walls, pass through the walls into extracapillary
spaces where metastases usually occur. SGE contains proteolytic enzyme inhibitors, thus reducing tumor cell extravasation.
However, SGE's action against tumor cell lodgement cannot
explain its effect when given on the same day as cyclophosphamide 4 days prior to tumor cell injection, because after 4 days the
extract is no longer active and would not have affected tumor
cells. One possible explanation cited by Dr Milas is that SGE also
contains inhibitors of enzymes associated with tissue injury and
thus reduced the tissue damage inflicted by cyclophosphamide
and local thoracic irradiation.
According to Dr Milas, these findings may have an impact on
the future treatment of patients with cytotoxic drugs or radiation:
"SGE or its active component might eventually be used with
primary drug or radiation treatment to prevent the possible
metastasis-enhancing effects of these modalities, especially in
instances in which the therapeutic effectiveness of the treatment
is uncertain."
(Physicians desiring additional information should write or call
Luka Milas, MD, PhD, Department of Experimental Radiotherapy,
MDAH Box 66, The University of Texas M. D. Anderson Hospital
and Tumor Institute at Houston, 6723 Bertner Avenue, Houston,
Texas 77030 (713) 792-3424.-ED)
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The University of Texas
M. D. Anderson Hospital and Tumor Institute
at Houston
Department of Head and Neck Surgery

Treatment of Cancer
in the Neck:
A Clinical Symposium
March 6-8, 1985
The Warwick Post Oak Hotel
Houston, Texas
Chairperson: David L. Larson, MD, Department of Head
and Neck Surgery
The conference will cover all aspects of treatment of
cancer in the neck including immunology, cell genetics,
pathology, surgery, radiotherapy, and chemotherapy.
For registration information, write or call the Office of
Conference Services, HMB Box 131, The University of
Texas M. D. Anderson Hospital and Tumor Institute at
Houston, 6723 Bertner Avenue, Houston, Texas 77030,
(713) 792-2222.

Clinical Conference Book On Lymphoma Now Available
Hodgkin's Disease and Non-Hodgkin's Lymphoma: New
Perspectives in lmmunopathology, Diagnosis, and Treatment, a
compilation of proceedings of the 27th Annual Clinical Conference held at UT MDAH in November 1983, is now available
(Raven Press, New York, 1984, 474 pages, $98.00). The volume,
edited by Richard J. Ford, Jr, MD, PhD, Department of Pathology,
Lillian M. Fuller, MD, Department of Clinical Radiotherapy, and
Fredrick B. Hagemeister, MD, Department of Hematology, presents the most recent findings of basic researchers and clinicians
on the etiology, epidemiology, diagnosis, and staging of Hodg-
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kin's disease and non-Hodgkin's lymphoma as well as the
treatment of patients with these diseases. Major areas of
discussion include: the tumor biology and pathology of lymphomas, oncogenes and other cytogenetic abnormalities in
lymphomas, new chemotherapy combinations, and immunotherapy with immunotoxins and bone marrow transplantation.
Because the lymphatic cancers offer the most instructive human
tumor model systems, the editors hope that the studies included
in this volume may provide insight into the causes of all
malignancies.
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